抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3170人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852744, encodeId=dfd91852e4462, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAHA：心脏结节病的皮质类固醇和免疫抑制剂治疗, objectType=article, longId=216642, objectId=9e162166421f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e162166421f, replyNumber=0, likeNumber=92, createdTime=2022-02-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e162166421f, moduleTitle=JAHA：心脏结节病的皮质类固醇和免疫抑制剂治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e162166421f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852721, encodeId=4f4b1852e211d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, objectType=article, longId=215061, objectId=7b66215061fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b66215061fc, replyNumber=0, likeNumber=80, createdTime=2022-03-08, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b66215061fc, moduleTitle=Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b66215061fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852769, encodeId=acb51852e69ab, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：呋喹替尼+PD-1抑制剂 vs 瑞戈非尼+ PD-1抑制剂治疗难治性微卫星稳定的转移性结直肠癌患者的疗效, objectType=article, longId=218182, objectId=cf9921818260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf9921818260, replyNumber=0, likeNumber=81, createdTime=2022-02-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf9921818260, moduleTitle=Front Oncol：呋喹替尼+PD-1抑制剂 vs 瑞戈非尼+ PD-1抑制剂治疗难治性微卫星稳定的转移性结直肠癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf9921818260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852796, encodeId=747e1852e969d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Mol Metab：钠-葡萄糖共转运体2抑制剂在糖尿病动脉粥样硬化斑块中的表达和炎症活动, objectType=article, longId=219808, objectId=93ce219808c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93ce219808c2, replyNumber=0, likeNumber=91, createdTime=2022-03-14, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93ce219808c2, moduleTitle=Mol Metab：钠-葡萄糖共转运体2抑制剂在糖尿病动脉粥样硬化斑块中的表达和炎症活动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93ce219808c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852885, encodeId=f42f185288571, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=用对质子泵抑制剂，有效预防抗血小板治疗所致消化道出血, objectType=article, longId=295414, objectId=b63729541464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b63729541464, replyNumber=0, likeNumber=90, createdTime=2022-12-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b63729541464, moduleTitle=用对质子泵抑制剂，有效预防抗血小板治疗所致消化道出血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b63729541464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852845, encodeId=2bee185284579, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, objectType=article, longId=291958, objectId=864c29195801, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864c29195801, replyNumber=0, likeNumber=103, createdTime=2022-07-01, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864c29195801, moduleTitle=Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864c29195801)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852788, encodeId=b91b1852e88fa, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Int J Cancer：甲状腺功能减退是PD-1抑制剂在肝癌中较好的抗肿瘤疗效预测因素。, objectType=article, longId=219038, objectId=74cc2190385f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74cc2190385f, replyNumber=0, likeNumber=82, createdTime=2022-06-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74cc2190385f, moduleTitle=Int J Cancer：甲状腺功能减退是PD-1抑制剂在肝癌中较好的抗肿瘤疗效预测因素。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74cc2190385f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852901, encodeId=b47b18529013c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet：Garadacimab可有效预防C1酯酶抑制剂缺乏性遗传性血管性水肿患者的水肿发作, objectType=article, longId=299975, objectId=14d32999e546, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14d32999e546, replyNumber=0, likeNumber=83, createdTime=2022-10-13, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14d32999e546, moduleTitle=Lancet：Garadacimab可有效预防C1酯酶抑制剂缺乏性遗传性血管性水肿患者的水肿发作, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14d32999e546)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852961, encodeId=895718529619c, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, objectType=article, longId=726365, objectId=c0f8e2636523, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0f8e2636523, replyNumber=0, likeNumber=81, createdTime=2022-07-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0f8e2636523, moduleTitle=长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0f8e2636523)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852952, encodeId=3ab2185295286, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Dermatolog Treat：JAK抑制剂联合紫外光疗可更有效的治疗白癜风, objectType=article, longId=724908, objectId=0f35e24908bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f35e24908bc, replyNumber=0, likeNumber=64, createdTime=2022-04-27, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f35e24908bc, moduleTitle=J Dermatolog Treat：JAK抑制剂联合紫外光疗可更有效的治疗白癜风, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f35e24908bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852732, encodeId=e3dd1852e3232, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况, objectType=article, longId=215780, objectId=dc30215e8019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc30215e8019, replyNumber=0, likeNumber=69, createdTime=2022-08-01, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc30215e8019, moduleTitle=Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc30215e8019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853000, encodeId=514018530008d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Science Translational Medicine：帕金森病治疗的一大步：LRRK2抑制剂临床试验评估, objectType=article, longId=729619, objectId=4952e2961904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4952e2961904, replyNumber=0, likeNumber=71, createdTime=2022-11-21, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4952e2961904, moduleTitle=Science Translational Medicine：帕金森病治疗的一大步：LRRK2抑制剂临床试验评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4952e2961904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852793, encodeId=918f1852e9331, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, objectType=article, longId=219389, objectId=f5d0219389bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d0219389bc, replyNumber=0, likeNumber=77, createdTime=2022-07-06, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d0219389bc, moduleTitle=Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5d0219389bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852904, encodeId=cfce1852904cb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=条件性CD28共刺激剂和双重PD-L1和CTLA-4检查点抑制剂davoceticept临床试验遭遇挫折：患者死亡, objectType=article, longId=300374, objectId=81c23003e459, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81c23003e459, replyNumber=0, likeNumber=92, createdTime=2022-12-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81c23003e459, moduleTitle=条件性CD28共刺激剂和双重PD-L1和CTLA-4检查点抑制剂davoceticept临床试验遭遇挫折：患者死亡, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81c23003e459)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852931, encodeId=a21c1852931b9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰, objectType=article, longId=723398, objectId=d22be233981c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d22be233981c, replyNumber=0, likeNumber=82, createdTime=2022-06-24, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d22be233981c, moduleTitle=ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d22be233981c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852764, encodeId=12cb1852e6440, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=CSCO大会速递 |NSCLC新型免疫检查点抑制剂研究进展, objectType=article, longId=217959, objectId=3c9821e9598e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c9821e9598e, replyNumber=0, likeNumber=52, createdTime=2022-06-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c9821e9598e, moduleTitle=CSCO大会速递 |NSCLC新型免疫检查点抑制剂研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c9821e9598e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852832, encodeId=7d0a18528320a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤, objectType=article, longId=221654, objectId=607c22165460, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=607c22165460, replyNumber=0, likeNumber=71, createdTime=2022-05-08, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=607c22165460, moduleTitle=Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=607c22165460)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852729, encodeId=29ef1852e2985, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, objectType=article, longId=215592, objectId=aefb21559219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aefb21559219, replyNumber=0, likeNumber=81, createdTime=2022-03-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aefb21559219, moduleTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aefb21559219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852958, encodeId=699a1852958dc, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle= Ann Med ：用酪氨酸激酶抑制剂治疗的患有慢性期慢性粒细胞白血病的青少年和年轻人的结果, objectType=article, longId=725905, objectId=f05ce2590585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f05ce2590585, replyNumber=0, likeNumber=79, createdTime=2022-05-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f05ce2590585, moduleTitle= Ann Med ：用酪氨酸激酶抑制剂治疗的患有慢性期慢性粒细胞白血病的青少年和年轻人的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f05ce2590585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852826, encodeId=5ddd18528264d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Hepatology：皮质类固醇剂量对免疫检查点抑制剂治疗肝炎的结局影响, objectType=article, longId=221275, objectId=f2552212e5e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2552212e5e3, replyNumber=0, likeNumber=95, createdTime=2021-12-02, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2552212e5e3, moduleTitle=Hepatology：皮质类固醇剂量对免疫检查点抑制剂治疗肝炎的结局影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2552212e5e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAHA：心脏结节病的皮质类固醇和免疫抑制剂治疗

2022-02-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Oncol：≥80岁的非转移性去势抵抗性前列腺癌患者是否可使用雄激素受体抑制剂治疗？

2022-03-08

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：呋喹替尼+PD-1抑制剂 vs 瑞戈非尼+ PD-1抑制剂治疗难治性微卫星稳定的转移性结直肠癌患者的疗效

2022-02-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Mol Metab：钠-葡萄糖共转运体2抑制剂在糖尿病动脉粥样硬化斑块中的表达和炎症活动

2022-03-14

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

用对质子泵抑制剂，有效预防抗血小板治疗所致消化道出血

2022-12-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Thorac Cancer：EGFR突变肺癌EGFR-TKIs治疗进展后应用免疫检查点抑制剂治疗的疗效

2022-07-01

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Int J Cancer：甲状腺功能减退是PD-1抑制剂在肝癌中较好的抗肿瘤疗效预测因素。

2022-06-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet：Garadacimab可有效预防C1酯酶抑制剂缺乏性遗传性血管性水肿患者的水肿发作

2022-10-13

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

长效C5补体抑制剂Ultomiris治疗视神经脊髓炎的III期试验取得积极结果

2022-07-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Dermatolog Treat：JAK抑制剂联合紫外光疗可更有效的治疗白癜风

2022-04-27

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况

2022-08-01

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Science Translational Medicine：帕金森病治疗的一大步：LRRK2抑制剂临床试验评估

2022-11-21

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Br J Cancer：CDK4/6抑制剂在恶性胸膜间皮瘤临床前模型中的疗效分析

2022-07-06

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

条件性CD28共刺激剂和双重PD-L1和CTLA-4检查点抑制剂davoceticept临床试验遭遇挫折：患者死亡

2022-12-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ACC/AHA/HFSA 2022：推荐SGLT-2抑制剂用于治疗心衰

2022-06-24

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

CSCO大会速递 |NSCLC新型免疫检查点抑制剂研究进展

2022-06-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：采用新型BTK抑制剂Zanubrutinib治疗复发/难治性边缘区淋巴瘤

2022-05-08

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性

2022-03-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Ann Med ：用酪氨酸激酶抑制剂治疗的患有慢性期慢性粒细胞白血病的青少年和年轻人的结果

2022-05-04

一叶知秋 (审核中...)

前往app查看评论内容

#抑制剂#

Hepatology：皮质类固醇剂量对免疫检查点抑制剂治疗肝炎的结局影响

2021-12-02

科室
- - 订阅+
  - 更多科室
工具
服务